Modification Delivery Time
Test code: 2639
PREVIOUS
Delivery Time
|
CURRENT
Delivery Time
|
Delivery time: 12 days
|
Delivery time: 5 days
|
Find the record of the test by clicking here
PREVIOUS
Delivery Time
|
CURRENT
Delivery Time
|
Delivery time: 12 days
|
Delivery time: 5 days
|
PREVIOUS
Delivery Time
|
CURRENT
Delivery Time
|
Delivery time: 1O days
|
Delivery time: 5 days
|
PREVIOUS
Delivery Time
|
CURRENT
Delivery Time
|
Delivery time: 13 days
|
Delivery time: 3 days
|
PREVIOUS
Method,Reference Values, Delivery term and Type of sample
|
CURRENT
Method, Reference Values, Delivery term and Type of sample
|
ENZYME IMMUNOASSAY
410 - 2620 pg/mL
Delivery term: 12 days
Sample: refrigerated plasma-EDTA
|
CHEMILUMINESCENCE
223 - 710 U/mL
Delivery term: 15 days
Sample: frozen serum
|
PREVIOUS
Reference values
|
CURRENT
Reference values
|
Up to 20 µg/L
|
NO EXPOSED: Less than 5 µg/L
B.E.I.: Less than 15 µg/L
|
New Test in CIC Catalog
Test Code: 4178
Sample: Whole blood - EDTA (5 ml) Conservation: Refrigerated Method: Sequencing Method Set Up Days: Daily Plazo de Entrega: 42 days Information: WITHOT ASSOCIATE PHENOTYPE Calpain-1 catalytic subunit is a protein that in humans is encoded by the CAPN1 gene. The calpains, calcium-activated neutral proteases, are nonlysosomal, intracellular cysteine proteases. The mammalian calpains include ubiquitous, stomach-specific, and muscle-specific proteins. The ubiquitous enzymes consist of heterodimers with distinct large, catalytic subunits associated with a common small, regulatory subunit. This gene encodes the large subunit of the ubiquitous enzyme, calpain 1. Links:Find the record of the test by clicking here
New Test in CIC Catalog
Test Code: 4177
Sample: Whole blood - EDTA (5 ml) Conservation: Refrigerated Method: Sequencing Method Set Up Days: Daily Plazo de Entrega: 42 days Information: Limb girdle muscular dystrophy (LGMD) constitutes a group of genetically determined, progressive muscle weakness disorders, in which the pelvic or shoulder girdle musculature is predominantly or primarily involved. The prevalence of autosomal recessive and sporadic LGMD cases has been estimated to 1/200,000. The age at onset is extremely variable. The rate of deterioration varies between families, intrafamilial variation is not very obvious. The disease has a much lesser severity than Duchenne muscular dystrophy, and can be very mild. Respiratory, but not cardiac complications have been described. Confinement to a wheelchair occurs at the earliest 11-18 years after the onset of symptoms. Serum creatine kinase (CK) activity is often more than 20 times elevated. LGMD2A is transmitted as an autosomal recessive form. Among theses cases, 33% are caused by mutation in the gene encoding the proteolytic enzyme calpain-3 (CAPN3) that is located on chromosome 15q15. No specific treatment is known and many patients receive physical therapy to prevent worsening of contractures. Links:Find the record of the test by clicking here
PREVIOUS
Reference values
|
CURRENT
Reference values
|
Less than
15 µg/g creatinine
B.E.I.:Less
than 35 µg/g creatinine
|
NO EXPOSED: Less than 20 µg/g creatinina
B.E.I.(Before work day): Less than 35 µg/g creatinina
B.E.I. (After work day): Less than 60 µg/g creatinina
|
PREVIOUS
Reference values
|
CURRENT
Reference values
|
<0.15 mg/24 horas
|
Less than 4 mg/24H
|
New Test in CIC Catalog
Test Code: 4175
Sample: Whole blood - EDTA (5 ml) Conservation: Refrigerated Method: Tri-Primer Polymerase Chain Reaction (TP-PCR) Set Up Days: Plazo de Entrega: 32 days Information: Differences in the dopamine and serotonin systems have been suggested as potential factors underlying interindividual variability in risk taking and in brain activation during the processing of feedback. The human dopamine transporter (DAT1) gene contains a variable number of tandem repeats (VNTR) in its 3?-untranslated region (UTR). The 9-repeat allele of the dopamine transporter (DAT) gene has been associated with increased striatal dopamine levels, and has been found to be related to increased sensitivity to reward. It is studied in relation with it´s possible implication with attention-deficit/hyperactivity disorder, risk taking behaviors, and various others neuropsychiatric disorders. Links:Find the record of the test by clicking here
PREVIOUS
Reference values
|
CURRENT
Reference values
|
0.20 - 1.50 µg/L
|
0.22 - 2.28 ng/ml
|
PREVIOUS
Sample
|
CURRENT
Sample and Relative information
|
Plasma-EDTA
| Tubes supplied by the laboratory
Three tubes: gray tube (control), red tube (TB antigens) and purple tube (mitogen).
|
New Test in CIC Catalog
Test Code: 4174
Sample: Serum (1 ml) Conservation: Refrigerated Method: Immunoblot (LOINC®: IB) Set Up Days: Daily Plazo de Entrega: 10 daysFind the record of the test by clicking here
PREVIOUS
Reference Values and Delivery term
|
CURRENT
Reference Values and Delivery term
|
MEN: 35,1 - 42,7 mg/L
WOMEN: 38,1 - 50 mg/L
Delivery term: 15 days
Refrigerated serum
|
MEN: 25 - 55 µg/L
WOMEN: 40 - 154 µg/L
Delivery term: 7 days
Frozen serum
|
PREVIOUS
Reference Values and Delivery term
|
CURRENT
Reference Values and Delivery term
|
1 - 16 µg/mL
*Indicative reference values
Delivery term: 25 days
|
2 - 10 mg/L
Delivery term: 12 days
|
PREVIOUS
Reference values
|
CURRENT
Reference values
|
Less than 0.045 mg/g creatinine
|
V.L.B. for Benzene: Less than 45 µg/g Creatinine
|
PREVIOUS
Delivery Time
|
CURRENT
Delivery Time
|
Delivery time: 30 days
|
Delivery time: 18 days
|